Cabaletta Bio, Inc. (CABA) Stock Analysis
A live, multi-source view of Cabaletta Bio, Inc. (CABA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc.
Sector: Healthcare · Industry: Biotechnology · United States · 154 employees · cabalettabio.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Cabaletta Bio, Inc. (CABA) had a market capitalization of $588.3M (forward -2.3) and a beta of 3.26; the shares traded in a 52-week range of $1.63 – $4.23 (107.1% over the year).
- Market cap
- $588.3M
- Enterprise value
- $388.9M
- Forward P/E
- -2.3
- Price / book
- 2.76
- EPS (trailing)
- $-1.38
- EPS (forward)
- $-1.48
- Payout ratio
- 0.0%
- 52-week range
- $1.63 – $4.23
- 52-week change
- 107.1%
- Beta
- 3.26
- Average volume
- 4.8M
- Shares outstanding
- 169.5M
- Short % of float
- 27.82%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Cabaletta Bio, Inc. (CABA) last closed at $2.74 (the last completed close before that scan).
Technicals at the scan: RSI 39 (neutral territory), price -12.5% versus its 20-day average, 20-day versus 50-day average spread +6.5%, MACD histogram -0.05.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 72/100.
Next scheduled company event: in 66 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for CABA in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
CABA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Cabaletta Bio, Inc. (CABA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell CABA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.